PennyStock101

LPTX - BREAK OUT - POSSIBLE 40% MOVE

Long
NASDAQ:LPTX   Leap Therapeutics, Inc
Leap Therapeutics , Inc. , formerly HealthCare Pharmaceuticals, Inc. , is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .

Leap Therapeutics , Inc. ( LPTX ), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a conference call on August 6, 2019, to provide a program update for DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. (Source: https://finance.yahoo.com/news/leap-ther...)

SHORT INTEREST
2.1M 07/15/19

P/E Current
-0.95

P/E Ratio (with extraordinary items)
-1.34

Average Recommendation: BUY

Average Target Price: 9.00

Your Intro To Penny Stock Trading Success...

1) Sign Up for our 100% Free Email Newsletter:
http://www.PennyStock101.org

2) Follow our Telegram Channel @ https://t.me/PennyStock101

3) Join our LIVE CHAT on Discord @ https://discord.gg/qSVhafy
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.